After Hours Summary: NDSN +3%, NQ +2% higher following earnings/guidance, DATA +6% on CEO news ... ZOES -17%, PINC -9% following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: NDSN +2.7%, NQ +2% (also updates on the FL Mobile divestment)
Companies trading higher in after hours in reaction to news: MBLX +65.2% (enters a binding LOI w/ CJ CheilJedang Corp for the sale of its biopolymer intellectual property and certain laboratory equipment for a total purchase price of $10 mln), DATA +5.7% (appoints Adam Selipsky as president and CEO effective September 16; current CEO Christian Chabot will continue to serve as chairman of its board), SCVL +5% (Chemical Financial will replace Supervalu in the S&P MidCap 400), ALIM +4.5% (Great Point Partners discloses 5.12% passive stake), CHFC +3.8% (to join S&P MidCap 400), EGRX +1.8% (ticking higher; to join S&P SmallCap 600), OCLR +1.4% (completes the exchanges for all $65 mln of its 6% Convertible Senior Notes due 2020), FCE.A +0.9% (to review strategic alternatives for its retail portfolio), G +0.4% (CFO disclosed purchase of 6250 shares, worth total of $147.7K), MU +0.3% (Micron executive Brian Shirley enters into prearranged trading plan for the sale of up to 162,257 shares of stock beginning in October), MEET +0.2% (files a Prospectus Supplement relating to the sale of up to 1 mln shares of common stock and 4 mln shares of common stock issuable upon exercise of warrants which may be offered by the selling shareholders),
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: BSPM -26.1% (also determines that there is substantial doubt as to its ability to continue as a going concern), ZOES -16.5%, PINC -8.7%
Companies trading lower in after hours in reaction to news: SPHS -26.1% (Sophiris Bio to offer and sell, subject to market and other conditions, its common shares and warrants to purchase additional common shares in an underwritten public offering), XCOM -25.7% (light volume; receives notice of termination of the Master Manufacturing Agreement between the Company and NSG Technology pursuant to the default and termination provisions contained therein), TKAI -17.6% (relinquishing today's gains; to discontinue enrollment in its ongoing ARMOR2 expansion clinical trial of galeterone in metastatic castration-resistant prostate cancer patients with acquired resistance to Xtandi, will not proceed with its planned study of galeterone in mCRPC patients who rapidly progress on either enzalutamide or Zytiga), LPTN -16.7% (files for $10 mln mixed shelf offering), COSI -14.9% (CFO resigns effective September 23, 2016, and co terminates CEO effective immediately), ROSG -2.9% (receives notice of rescission of conditional approval from the New York State Department of Health for four of its allele-specific PCR -based assays to test for BRAF, EGFR, KRAS and NRAS mutations in various cancers)